APC-resistance Is a Risk Factor for Postoperative Thromboembolism in Elective Replacement of the Hip or Knee – A Prospective Study

Tomas L. Lindahl; Tom H. Lundahl; Lennart Nilsson; Christer A. Andersson

doi:10.1055/s-0037-1614410

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1999; 81(01): 18-21
DOI: 10.1055/s-0037-1614410

Review Article

Schattauer GmbH

APC-resistance Is a Risk Factor for Postoperative Thromboembolism in Elective Replacement of the Hip or Knee – A Prospective Study

Tomas L. Lindahl

¹ From the Departments of Clinical Chemistry, University Hospital, Linköping

,

Tom H. Lundahl

²Västervik Hospital, Västervik, University Hospital, Linköping, Sweden

,

Lennart Nilsson

³Northern Älvsborg Hospital, Trollhättan, University Hospital, Linköping, Sweden

,

Christer A. Andersson

⁴Department of Orthopaedic Surgery, University Hospital, Linköping, Sweden

› Author Affiliations

References
1 Turpie AGG, Levine MN, Hirsch J. et al A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315: 925-9.
2 Bergqvist D. Review of clinical trials of low molecular weight heparins. Clinical review. Eur J Surg 1992; 158: 67-8.
3 Bergqvist B, Benoni G, Björgell O. et al Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335: 696-700.
4 Dahl O E, Andreassen G, Aspelin T. et al Prolonged thromboprophylaxis following hip replacement surgery – results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin^®). Thromb Haemost 1997; 77: 26-31.
5 Planes A, Vochelle N, Darmon JY, Fagola M, Huet Y. Risk of deep venous thrombosis after hospital discharge in patients undergoing total hip replacement. Double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348: 224-8.
6 Lassen MR, Borris LC. on behalf of the Danish Prolonged Thromboprophylaxis Study Group. Prolonged thromboprophylaxis with low molecular weight heparin (Fragmin) after total hip arthroplasty- a placebo-controlled study. Thromb Haemost 1995; 73: 1104.
7 Bergqvist D, Jendteg S, Johansen L, Persson U, Ödegaard K. Cost of long-term complications of the deep venous thrombosis of the lower extremities: An analysis of a defined patient population in Sweden. Ann Inter Med 1997; 126: 454-7.
8 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterized by a poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Nat Acad Sci 1993; 90: 1004-8.
9 Svensson P J, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
10 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
11 Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
12 Holm J, Zöller B, Berntorp E, Erhardt L, Dahlbäck B. Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries. J Int Med 1996; 239: 221-6.
13 Svensson PJ, Benoni G, Fredin H, Björgell O, Nilsson P, Hedlund U, Nylander G, Bergqvist D, Dahlbäck B. Female gender and resistance to activated protein C (FV:Q⁵⁰⁶) as potential risk factors for thrombosis after elective hip arthroplasty. Thromb Haemost 1997; 78: 993-6.
14 Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593-6.
15 Ridker PM, Hennekens CH, Lindpainter K. et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. New Engl J Med 1995; 332: 912-7.
16 Dahlbäck B, Hillarp A, Rosen S, Zöller B. Resistance to activated protein C, the FV:Q⁵⁰⁶ allele, and venous thrombosis. Am Hematol 1996; 72: 166-76.
17 Svensson P J, Zöller B, Dahlbäck B. Evaluation of original and modified APC-resistance test in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thromb Haemost 1997; 77: 332-5.
18 In: Altman DG. ed. Practical statistics for medical research, 1^st edn. London, UK: Chapman & Hall; 1996: 229-72.
19 Ryan DH, Mark AC, Ginsberg JS, Francis CW. Relation of Factor V Leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery. Ann Intern Med 1998; 128: 270-6.